The DOI matches its Crossref record; 53 of the 54 references it cites were found in a registry or an index.
Membrane-destabilizing ionizable phospholipids for organ-selective mRNA delivery and CRISPR–Cas gene editing
Open accessAbstract
Endosomal escape remains a fundamental barrier hindering the advancement of nucleic acid therapeutics. Taking inspiration from natural phospholipids that comprise biological membranes, we report the combinatorial synthesis of multi-tailed ionizable phospholipids (iPhos) capable of delivering messenger RNA or mRNA/single-guide RNA for gene editing in vivo. Optimized iPhos lipids are composed of one pH-switchable zwitterion and three hydrophobic tails, which adopt a cone shape in endosomal acidic environments to facilitate membrane hexagonal transformation and subsequent cargo release from endosomes. Structure-activity relationships reveal that iPhos chemical structure can control in vivo efficacy and organ selectivity. iPhos lipids synergistically function with various helper lipids to formulate multi-component lipid nanoparticles (called iPLNPs) for selective organ targeting. Zwitterionic, ionizable cationic and permanently cationic helper lipids enable tissue-selective mRNA delivery and CRISPR-Cas9 gene editing in spleen, liver and lungs (respectively) following intravenous administration. This rational design of functional phospholipids demonstrates substantial value for gene editing research and therapeutic applications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Organ selectivity can also be achieved by adjusting the proportions of lipid components, for example, to design spleen-targeted mRNA vaccines26,27 or lung-targeted genome editing delivery systems114,134.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [114]
In the citing paper
“Moreover, the delivery efficacy of mRNA could be improved, for example, by rational design of lipids through modulation of head groups and hydrophobic tails to increase cellular uptake and endosomal escape of lipid nanoparticle–mRNA formulations64,66,76–78,88,97,100,114,140,141.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [114]
In the citing paper
“For example, alteration of the alkyl length of a lipid results in selective accumulation of lipid nanoparticle–mRNA formulations in the liver or spleen114.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [114]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
RNA-Guided Human Genome Engineering via Cas9
Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., & Church, G. M. (2013) · Science · doi:10.1126/science.1232033 · Cited by 9,210
Membrane lipids: where they are and how they behave
van Meer, G., Voelker, D. R., & Feigenson, G. W. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2330 · Cited by 7,157
Cheng, Q., Wei, T., Farbiak, L., Johnson, L. T., Dilliard, S. A., & Siegwart, D. J. (2020) · Nature Nanotechnology · doi:10.1038/s41565-020-0669-6 · Cited by 2,383
Self-citationRational design of cationic lipids for siRNA delivery
Semple, S. C., Akinc, A., Chen, J., Sandhu, A. P., Mui, B. L., Cho, C. K., Sah, D. W. Y., Stebbing, D., Crosley, E. J., Yaworski, E., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1602 · Cited by 1,822
Delivery materials for siRNA therapeutics
Kanasty, R., Dorkin, J. R., Vegas, A., & Anderson, D. (2013) · Nature Materials · doi:10.1038/nmat3765 · Cited by 1,800
Gilleron, J., Querbes, W., Zeigerer, A., Borodovsky, A., Marsico, G., Schubert, U., Manygoats, K., Seifert, S., Andree, C., Stöter, M., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2612 · Cited by 1,681
The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs
Akinc, A., Maier, M. A., Manoharan, M., Fitzgerald, K., Jayaraman, M., Barros, S., Ansell, S., Du, X., Hope, M. J., Madden, T. D., et al. (2019) · Nature Nanotechnology · doi:10.1038/s41565-019-0591-y · Cited by 1,636
Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo
Jayaraman, M., Ansell, S. M., Mui, B. L., Tam, Y. K., Chen, J., Du, X., Butler, D., Eltepu, L., Matsuda, S., Narayanannair, J. K., et al. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201203263 · Cited by 1,267
Cited by
Sorted by citations
Items 201–300 of 652
Kim, M., Jeong, M., Lee, G., Lee, Y., Park, J., Jung, H., Im, S., Yang, J., Kim, K., & Lee, H. (2023) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10556 · Cited by 35
“10 For the optimization of LNP formulation, we compared the potency of 244cis LNP with two different PEG lipids: C16-PEG2k ceramide and DMG-PEG2k.”
MethodCRISPR/Cas9-based application for cancer therapy: Challenges and solutions for non-viral delivery
Lin, Y., Feng, K.-K., Lu, J.-Y., Le, J., Li, W.-L., Zhang, B., Li, C., Song, X.-H., Tong, L.-W., & Shao, J. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.08.028 · Cited by 38
Ge, K., Bai, Z., Wang, J., Li, Z., Gao, F., Liu, S., Zhang, L., Gao, F., & Xie, C. (2025) · Advanced Materials · doi:10.1002/adma.202418872 · Cited by 36
Self-citationDemystifying mRNA vaccines: an emerging platform at the forefront of cryptic diseases
Rouf, N. Z., Biswas, S., Tarannum, N., Oishee, L. M., & Muna, M. M. (2022) · RNA Biology · doi:10.1080/15476286.2022.2055923 · Cited by 39
“Furthermore, incorporating these ionisable phospholipids with other helper lipids to form hybrid LNPs (iPLNPs) led to mRNA delivery selectively to specific organs in vivo in mice [115].”
BackgroundMa, Y., & Fenton, O. S. (2023) · Advanced Therapeutics · doi:10.1002/adtp.202200305 · Cited by 39
Non-viral nucleic acid delivery approach: A boon for state-of-the-art gene delivery
Sahu, K. K., Pradhan, M., Singh, D., Singh, M. R., & Yadav, D. K. (2023) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2023.104152 · Cited by 36
An overview of lipid constituents in lipid nanoparticle mRNA delivery systems
Wu, S., Lin, L., Shi, L., & Liu, S. (2024) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1978 · Cited by 35
Self-citationAdvancing cancer gene therapy: the emerging role of nanoparticle delivery systems
Wang, M., Liu, H., Huang, J., Cai, T., Xu, Z. P., & Zhang, L. L. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03433-8 · Cited by 37
“For example, to achieve specific delivery of Cas9 mRNA and sgRNA to tissues, multi-component LNPs were engineered using ioniz-able phospholipids that can disrupt cellular membranes [142].”
mRNA delivery via non-viral carriers for biomedical applications
Shuai, Q., Zhu, F., Zhao, M., & Yan, Y. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.121020 · Cited by 35
Development of nucleic acid medicines based on chemical technology
Kawamoto, Y., Wu, Y., Takahashi, Y., & Takakura, Y. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114872 · Cited by 34
Moayedpour, S., Broadbent, J., Riahi, S., Bailey, M., Thu, H. V., Dobchev, D. A., Balsubramani, A., dos Santos, R. N., Kogler-Anele, L., Corrochano-Navarro, A., et al. (2024) · Bioinformatics · doi:10.1093/bioinformatics/btae342 · Cited by 38
“The binary target dataset provided by Ding et al. (2023) and the multiclass target dataset, which we curated, based on the findings from Liu et al. (2021).”
InfluentialLyu, Y., Yang, X., Yang, L., Dai, J., Qin, H., Zhou, Y., Huang, Y., Wang, Y., Wu, D., Shuai, Q., et al. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.07.011 · Cited by 37
Zhao, Y., Tian, Z., Wang, J., Cui, M., Cao, Z., Liu, P., Li, R., Cai, S., Hu, Y., Ma, Y., et al. (2025) · Science Advances · doi:10.1126/sciadv.ady6460 · Cited by 37
“1C) ( 27 , 28 ).”
Targeting and tracking mRNA lipid nanoparticles at the particle, transcript and protein level
Kang, D. D., Marks, A. R., Morlà‐Folch, J., Dong, Y., Brown, B. D., & Teunissen, A. J. P. (2025) · Nature Biomedical Engineering · doi:10.1038/s41551-025-01511-8 · Cited by 45
“Thus, approaches for targeting LNPs to specific tissues or cell types using neutral or negatively charged helper lipids have been developed 52,83,108,109 .”
Meng, N., & Grimm, D. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00642-z · Cited by 35
“by data from a hemolysis model and by a fluorescence resonance energy transfer (FRET) assay.(1) A general concern in vector research is translation of in vitro vector functionality to an in vivo setting.”
BackgroundMethodInfluentialSpleen-targeted nanosystems for immunomodulation
Wang, F., Lou, J., Gao, X., Zhang, L., Sun, F., Wang, Z., Ji, T., & Qin, Z. (2023) · Nano Today · doi:10.1016/j.nantod.2023.101943 · Cited by 36
Zwitterionic materials for nucleic acid delivery and therapeutic applications
He, S., & Liu, S. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.12.017 · Cited by 33
Self-citationLombaerde, E. D., Chen, Y., Ye, T., Deckers, J., Mencarelli, G., Swarte, K. D., Lauwers, H., Coen, R. D., Kasmi, S., Bevers, S., et al. (2024) · Advanced Functional Materials · doi:10.1002/adfm.202310623 · Cited by 36
Paracyclophane-based ionizable lipids for efficient mRNA delivery in vivo
Wu, S., Su, K., Yan, X., Shi, L., Lin, L., Ren, E., Zhou, J., Zhang, C., Song, Y., & Liu, S. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.10.028 · Cited by 35
Self-citationUnderstanding of endo/lysosomal escape of nanomaterials in biomedical application
Wang, X., Li, H., Chen, C., & Liang, Z. (2025) · Smart Molecules · doi:10.1002/smo.20240017 · Cited by 37
Advancements in CRISPR/Cas systems for disease treatment
Xu, Y., Le, H., Wu, Q., Wang, N., & Gong, C. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.05.007 · Cited by 35
“Similarly, regulating the pH and structure of phospholipids allows organ targeting 304 .”
Zhao, Z., Shan, X., Ding, J. X., Ma, B., Li, B., Huang, W., Yang, Q., Fang, Y., Chen, J. C., Song, C., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-61688-z · Cited by 46
Self-citationLian, Z., Zheng, L., Liu, S., Zhang, J., Zhou, J. J., Wu, J., Ouyang, S., Li, J., & Yang, H. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.5c05367 · Cited by 35
Self-citationNanomaterials with changeable physicochemical property for boosting cancer immunotherapy
Ni, Q., Xu, F., Wang, Y., Li, Y., Qing, G., Zhang, Y., Zhong, J., Li, J., & Liang, X. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.01.003 · Cited by 33
Engineering brain-derived neurotrophic factor mRNA delivery for the treatment of Alzheimer’s disease
Li, H., Cao, Y., Ye, J., Yang, Z., Chen, Q., Liu, X., Zhang, B., Qiao, J., Tang, Q., Yang, H., et al. (2023) · Chemical Engineering Journal · doi:10.1016/j.cej.2023.143152 · Cited by 32
Gu, W., An, J., Li, Y., Yang, Y., Wang, S., Shan, H., Li, S., Li, H., Liu, G., Li, K., et al. (2023) · Advanced Materials · doi:10.1002/adma.202301686 · Cited by 32
Le, Z., Pan, Q., He, Z., Liu, H., Shi, Y., Liu, L., Liu, Z., Yuan, P., & Chen, Y. (2023) · ACS Central Science · doi:10.1021/acscentsci.3c00207 · Cited by 32
Bioinspired Spatiotemporal Management toward RNA Therapies
Ma, Y., Li, S., Lin, X., & Chen, Y. (2023) · ACS Nano · doi:10.1021/acsnano.3c08219 · Cited by 32
Delivery of nucleic acids using nanomaterials
Qin, Y., Ou, L., Zha, L., Zeng, Y., & Li, L. (2023) · Molecular Biomedicine · doi:10.1186/s43556-023-00160-0 · Cited by 35
“They found that adding DDAB to the top-performing iPhos 9A1P9 effectively mediated enhanced mRNA delivery and CRISPR-Cas9 gene editing in the lungs [243].”
BackgroundSystemic reprogramming of tumour immunity via IL-10-mRNA nanoparticles
Chuang, L. I. U., Huang, X., Chen, K., Xiong, S., Yaremenko, A. V., Zhen, X., You, X., Rossignoli, F., Tang, Y., Koo, S., et al. (2025) · Nature Nanotechnology · doi:10.1038/s41565-025-01980-7 · Cited by 33
Wang, Q., Jiang, Q., Li, D., Yang, Z., Gao, L., Liu, F., Li, C., Feng, Y., He, Z., Luo, C., et al. (2023) · Chinese Chemical Letters · doi:10.1016/j.cclet.2023.108683 · Cited by 31
Non-viral nanocarriers for CRISPR-Cas9 gene editing system delivery
Tang, X., Wang, Z., Zhang, Y., Mu, W., & Han, X. (2022) · Chemical Engineering Journal · doi:10.1016/j.cej.2022.135116 · Cited by 30
Ghani, M. W., Iqbal, A., Ghani, H., Bibi, S., Wang, Z., & Pei, R. (2023) · Journal of Materials Chemistry B · doi:10.1039/d2tb02610d · Cited by 32
RNA Nanomedicine: Delivery Strategies and Applications
Byun, J., Wu, Y., Park, J.-W., Kim, J. S., Li, Q., Choi, J., Shin, N., Lan, M., Cai, Y., Lee, J., et al. (2023) · The AAPS Journal · doi:10.1208/s12248-023-00860-z · Cited by 32
“Intravenous administration of this nanocarrier loaded with CRISPR/Cas9 RNA led to a reduction in serum levels of low-density lipoprotein cholesterol and triglycerides.”
BackgroundInfluentialNanotechnology‐based CRISPR/Cas9 delivery system for genome editing in cancer treatment
Zhou, S., Li, Y., Wu, Q., & Gong, C. (2024) · MedComm – Biomaterials and Applications · doi:10.1002/mba2.70 · Cited by 30
Cationic Lipid Pairs Enhance Liver-to-Lung Tropism of Lipid Nanoparticles for In Vivo mRNA Delivery
Zeng, G., He, Z., Yang, H., Gao, Z., Ge, X., Liu, L., Liu, Z., & Chen, Y. (2024) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.4c02415 · Cited by 31
Lombaerde, E. D., Cui, X., Chen, Y., Zhong, Z., Deckers, J., Mencarelli, G., Opsomer, L., Wang, H., Baere, J. D., Lienenklaus, S., et al. (2024) · ACS Nano · doi:10.1021/acsnano.4c09677 · Cited by 31
A Versatile Strategy to Transform Cationic Polymers for Efficient and Organ‐Selective mRNA Delivery
Lin, L., Su, K., Zhang, X., Shi, L., Yan, X., Fu, Q., Yao, K., Siegwart, D. J., & Liu, S. (2025) · Angewandte Chemie International Edition · doi:10.1002/anie.202500306 · Cited by 30
Self-citationResearch Progress on Nanoparticles-Based CRISPR/Cas9 System for Targeted Therapy of Tumors
Nie, D., Guo, T., Yue, M., Li, W., Zong, X., Zhu, Y., Huang, J., & Lin, M. (2022) · Biomolecules · doi:10.3390/biom12091239 · Cited by 33
“iPhos Cas9 mRNA and sgRNA ~91% (hepatocytes) ~34% (lung endothelial cells) ~20% (lung epithelial cells) ~13% (lung immune cells) ~30% (splenic macrophages) 6% (Splenic B cells) in vivo [76]”
BackgroundNext-generation materials for RNA–lipid nanoparticles: lyophilization and targeted transfection
Wang, T., Sung, T., Yu, T., Lin, H.-Y., Chen, Y.-H., Zhu, Z.-W., Gong, J., Pan, J., & Higuchi, A. (2023) · Journal of Materials Chemistry B · doi:10.1039/d3tb00308f · Cited by 31
Kang, S. W., Kang, O.-J., Lee, J., Kim, H.-J., Jung, H., Kim, H., Lee, S., Kim, Y., & Choi, E. K. (2024) · PLoS ONE · doi:10.1371/journal.pone.0298815 · Cited by 29
Impact of Lipid Tail Length on the Organ Selectivity of mRNA-Lipid Nanoparticles
Hashiba, K., Taguchi, M., Sakamoto, S., Otsu, A., Maeda, Y., Suzuki, Y., Ebe, H., Arimichi, O., Harashima, H., & Sato, Y. (2024) · Nano Letters · doi:10.1021/acs.nanolett.4c02566 · Cited by 29
Zhao, Y., Wang, Z. M., Song, D., Chen, M., & Xu, Q. (2024) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2024.102499 · Cited by 30
The Interplay of Endosomal Escape and RNA Release from Polymeric Nanoparticles
Cheung, T. H., & Shoichet, M. S. (2025) · Langmuir · doi:10.1021/acs.langmuir.4c05176 · Cited by 33
Precisely Targeted Nanoparticles for CRISPR-Cas9 Delivery in Clinical Applications
Liu, X., Gao, M., & Bao, J. (2025) · Nanomaterials · doi:10.3390/nano15070540 · Cited by 31
Dual SORT LNPs for multi-organ base editing
Kim, M., Song, E. S., Chen, J. C., Chatterjee, S., Sun, Y., Lee, S. M., Wu, S., Patel, P., Tian, Z., Kantor, A., et al. (2025) · Nature Biotechnology · doi:10.1038/s41587-025-02675-z · Cited by 39
Self-citationArtificial intelligence-guided design of lipid nanoparticles for mRNA delivery
Su, K., Qiu, J., Xu, T., & Liu, S. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.11.029 · Cited by 39
Self-citationElwakil, M. M. A., Suzuki, R., Khalifa, A. M., Elshami, R. M., Isono, T., Elewa, Y. H. A., Sato, Y., Nakamura, T., Satoh, T., & Harashima, H. (2023) · Advanced Functional Materials · doi:10.1002/adfm.202303795 · Cited by 30
Wang, Q., Bu, C., Dai, Q., Chen, J., Zhang, R., Zheng, X., Ren, H., Xin, X., & Li, X. (2024) · Advanced Science · doi:10.1002/advs.202309748 · Cited by 29
Developing mRNA Nanomedicines with Advanced Targeting Functions
Wang, J., Cai, L., Li, N., Luo, Z., Ren, H., Zhang, B., & Zhao, Y. (2025) · Nano-Micro Letters · doi:10.1007/s40820-025-01665-9 · Cited by 33
Design principles of lipid nanoparticles for RNA delivery
Arral, M. L., & Whitehead, K. A. (2026) · Nature Reviews Bioengineering · doi:10.1038/s44222-026-00401-1 · Cited by 41
Wu, S., Xia, Y., Hu, Y., & Ma, G. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113871 · Cited by 27
Ionizable drug delivery systems for efficient and selective gene therapy
Zhang, Y., Guo, R., Chen, Y., Li, T., Du, W.-Z., Xiang, R., Guan, J., Li, Y., Huang, Y., Yu, Z., et al. (2023) · Military Medical Research · doi:10.1186/s40779-023-00445-z · Cited by 27
“The positive charge ratio is increased to allow for a convergent transfer of tissue from the liver to the lung, and increasing the negative charge of certain structures can promote spleen-specific transport [24].”
BackgroundResultInfluentialA Spleen‐Targeted Tolerogenic mRNA‐LNPs Vaccine for the Treatment of Experimental Asthma
Wang, F., Lou, J., Lou, X., Wu, F., Gao, X., Yao, X., Wan, J., Duan, X., Deng, W., Ma, L., et al. (2025) · Advanced Science · doi:10.1002/advs.202412543 · Cited by 27
Su, L.-J., Wang, N.-N., Luo, R.-S., Ji, Z.-H., Gu, H., Yang, C., Xu, M.-X., Zhang, J., Chen, Q., Yu, M., et al. (2026) · Nature Biomedical Engineering · doi:10.1038/s41551-026-01640-8 · Cited by 33
Zhang, H., Ding, F., Zhu, Z., Sun, Q., & Yang, C. (2022) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2022.122489 · Cited by 25
Theranostic Lipid Nanoparticles for Renal Cell Carcinoma
Mao, X., Wang, G., Wang, Z., Duan, C., Wu, X., & Xu, H. (2023) · Advanced Materials · doi:10.1002/adma.202306246 · Cited by 29
Advancing mRNA technologies for therapies and vaccines: An African context
Kairuz, D., Samudh, N., Ely, A., Arbuthnot, P., & Bloom, K. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1018961 · Cited by 25
“SORT was also applied in a study that designed multitailed ionizable phospholipids (iPhos) to improve RNA delivery (104).”
MethodInsights into the formulation of lipid nanoparticles for the optimization of mRNA therapeutics
Jiao, X., He, X., Qin, S., Yin, X., Song, T., Duan, X., Shi, H., Jiang, S., Zhang, Y., & Song, X. (2024) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1992 · Cited by 28
Intelligent Design of Lipid Nanoparticles for Enhanced Gene Therapeutics
Yuan, Y., Li, Y., Li, G., Lei, L., Huang, X., Li, M., & Yao, Y. (2025) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.4c00925 · Cited by 28
Nano Approaches to Nucleic Acid Delivery: Barriers, Solutions, and Current Landscape
Gonzalez, J. C., Park, K. W., Evans, D. B., Sharma, R. B., Sahaym, O., Gopalakrishnan, S., Dar, A. I., Valdez, T. A., & Sharma, A. (2025) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.70010 · Cited by 31
“This transformation enables efficient endosomal escape, leading to faster and more effective protein expression or genome editing (Hou et al. 2021; Liu et al. 2021).”
Ge, X., He, Z., Yang, H., Pan, X., Yan, L., Shi, Y., Chen, Y., & Liu, Z. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113906 · Cited by 25
Amoako, K. A., Mokhammad, A., Malik, A., Yesudasan, S., Wheba, A., Olagunju, O., Gu, S. X., Yarovinsky, T. O., Faustino, E. V. S., Nguyen, J., et al. (2025) · Frontiers in Medical Technology · doi:10.3389/fmedt.2025.1591119 · Cited by 31
Overcoming delivery barriers with LNPs
Jadhav, S. G., & Dowdy, S. F. (2021) · Nature Materials · doi:10.1038/s41563-021-00988-3 · Cited by 25
Goldman, R., Murthy, N. T. V., Trent, N., Balakrishnan, A., Chivukula, S. V., Danz, H., Tibbitts, T. J., Dias, A., Vargas, J., Cooper, D. L., et al. (2023) · Biomaterials · doi:10.1016/j.biomaterials.2023.122243 · Cited by 26
Prime Editing: A Revolutionary Technology for Precise Treatment of Genetic Disorders
Li, M., Lin, Y., Cheng, Q., & Wei, T. (2025) · Cell Proliferation · doi:10.1111/cpr.13808 · Cited by 28
“LNPs have made significant progress in cell and animal models with genomic abnormalities by delivering gene editing tools for various applications, including CRISPR/ Cas9 for gene knockout, and CRISPR/Cas/ssDNA as well as base editors for precise gene correction [141, 143, 144, 157, 158].”
Self-citationNonviral Delivery of CRISPR/Cas Systems in mRNA Format
Liu, Z., Li, Z., & Li, B. (2022) · Advanced NanoBiomed Research · doi:10.1002/anbr.202200082 · Cited by 25
Spherical nucleic acids-based nanoplatforms for tumor precision medicine and immunotherapy
Liu, S., Yu, C., & Wei, H. (2023) · Materials Today Bio · doi:10.1016/j.mtbio.2023.100750 · Cited by 25
“For example, LNPs suffer from a single targeting property to the liver [18] and compromised endosomal escape capacity after endocytosis [19,20].”
BackgroundSelf-citationZhang, T., Ding, J., Lv, Q., Zhao, M., Liu, Y., Wang, Q., Chen, Y., Zhao, H., Ren, H., Jiang, W., et al. (2024) · Materials & Design · doi:10.1016/j.matdes.2024.113097 · Cited by 24
Advances in targeted delivery of mRNA into immune cells for enhanced cancer therapy
Huang, L., Huang, Z., Zhang, Y., Lin, C., Zhao, Z., Li, R., Saw, P. E., & Xu, X. (2024) · Theranostics · doi:10.7150/thno.93745 · Cited by 24
“[10] Table 2.”
Shuvaev, V. V., Tam, Y. K., Lee, B. W., Myerson, J. W., Herbst, D. A., Kiseleva, R. Y., Glassman, P. M., Parhiz, H., Alameh, M., Pardi, N., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2409266122 · Cited by 25
Cao, L., Yu, Y.-F., Li, Z., Zhong, N., Wang, G.-R., Xiao, Y., Liu, B., Wu, Q., Feng, C., & Bu, L. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02590-6 · Cited by 28
“Alternating the alkyl length of a lipid or changing the intermediate connecting group of LNP from an ester bond to an amide bond in the tail can also change the organ targeting of LNP to liver or lung [122, 123].”
BackgroundAdvancing mRNA Therapeutics: The Role and Future of Nanoparticle Delivery Systems
Li, J., Zhang, Y., Yang, Y., & Sun, T. (2024) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.4c00276 · Cited by 24
Interaction design in mRNA delivery systems
Yu, M., Lin, L., Zhou, D., & Liu, S. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.11.038 · Cited by 25
Self-citationFluorinated Ionizable Lipids for Efficient Spleen-Targeted mRNA Delivery in Cancer Immunotherapy
Zhang, Y., Shao, B., Jiang, K., Cen, J., Liu, Y., Tan, J., Zhang, L., Li, K., You, C., He, Z., et al. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.5c13982 · Cited by 24
Self-citationNanoparticle-based strategy in CAR-T cell immunotherapy: challenges, implications, and perspectives
Shang, D., Zhou, Z., Shi, R., Wang, Z., Zhang, P., Fu, P., Li, H., Cheng, G., Qin, H., Xie, Z., et al. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02476-7 · Cited by 26
“Strategies include modifying NP composition (e.g., employing ionizable lipids, proton sponge molecules, or calcium ions) or designing specific structures like cuboplex nanostructures [223– 226].”
mRNA delivery technologies: Toward clinical translation
Gómez-Aguado, I., Rodríguez-Castejón, J., Beraza-Millor, M., Rodríguez‐Gascón, A., del Pozo‐Rodríguez, A., & Solinís, M. Á. (2022) · International review of cytology · doi:10.1016/bs.ircmb.2022.04.010 · Cited by 23
Zhao, H., Ma, S., Qi, Y., Gao, Y., Zhang, Y., Li, M., Chen, J., Song, W., & Chen, X. (2024) · Materials Horizons · doi:10.1039/d3mh02066e · Cited by 21
mRNA medicine: Recent progresses in chemical modification, design, and engineering
Hou, X., Shi, J., & Xiao, Y. (2024) · Nano Research · doi:10.1007/s12274-024-6978-6 · Cited by 24
Liu, Q., Gao, Z., Zhang, X., Duan, Q., Zhang, Y., Midgley, A. C., Li, J., Liu, R., Zhu, M., Kong, D., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-56414-8 · Cited by 22
“The endo-lysosomalbarrier poses a signi fi cant hurdle for ef fi cient intracellular delivery, typically resulting in less than 1% of payloads beingreleasedintothecytoplasm 33,34 .”
Inflammatory cytokines mediate the induction of and awakening from metastatic dormancy
Pereira, P., Panier, J., Nater, M., Herbst, M., Calvanese, A. L., Köksal, H., Castañón, H., Cecconi, V., de Lara, P. T., Pascolo, S., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.115388 · Cited by 22
Non‐Viral Gene Delivery Systems: Current Advances and Therapeutic Applications
Wang, F., Liang, L., Wang, C., Zhang, C., Ye, Y., Dou, L., Shi, L., Zhou, D., & Sun, X. (2025) · Chemistry - An Asian Journal · doi:10.1002/asia.202500684 · Cited by 22
Wang, C., Pan, Q., Chen, S., Zhang, Y., Xu, X., Yan, X., Guo, J., Chen, X., Li, B., Ganzorig, C., et al. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.5c08376 · Cited by 22
Recent Advances in Lipid Nanoparticles: Nucleic Acid Therapeutics and Targeting Strategies
Sarmah, S., Baidya, S., & De, M. (2025) · Small · doi:10.1002/smll.202506812 · Cited by 25
mRNA vaccines: immunogenicity and quality characteristics
Quan, Y., Yang, H., Li, W., & Li, L. X. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03800-5 · Cited by 27
“For instance, novel helper lipids designed by Gomi et al. enable targeted delivery of LNPs to the spleen and secondary lymphoid tissues, while Liu et al. enhanced mRNA delivery efficiency by screening ionizable phospholipids [102, 119, 120].”
Li, B., Wang, J., Ye, P., Liu, C., Ming, Y., Yang, B., He, D., Lai, W., Guo, L., Zhao, M., et al. (2026) · Journal of the American Chemical Society · doi:10.1021/jacs.5c14271 · Cited by 22
A cationic lipid with advanced membrane fusion performance for pDNA and mRNA delivery
Wei, Y., He, T., Bi, Q., Yang, H., Hu, X., Jin, R., Liang, H., Zhu, Y., Tong, R., & Nie, Y. (2023) · Journal of Materials Chemistry B · doi:10.1039/d2tb02783f · Cited by 21
The clinical progress and challenges of mRNA vaccines
Yu, M., Wang, N., Zhu, J., & Lin, Y. (2023) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1894 · Cited by 23
Natural components as surface engineering agents for CRISPR delivery
Rabiee, N. (2023) · Environmental Research · doi:10.1016/j.envres.2023.116333 · Cited by 21
Responsive Nucleic Acid-Based Organosilica Nanoparticles
Picchetti, P., Volpi, S., Rossetti, M., Dore, M. D., Trinh, T., Biedermann, F., Neri, M., Bertucci, A., Porchetta, A., Corradini, R., et al. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.3c00393 · Cited by 21
Picchetti, P., Volpi, S., Sancho‐Albero, M., Rossetti, M., Dore, M. D., Trinh, T., Biedermann, F., Neri, M., Bertucci, A., Porchetta, A., et al. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.3c04345 · Cited by 21
Bogaert, B., Debisschop, A., Ehouarne, T., Eeckhoutte, H. P. V., Volder, J. D., Jacobs, A., Pottie, E., Rycke, R. M. D., Crabbé, A., Mestdagh, P., et al. (2024) · Nano Letters · doi:10.1021/acs.nanolett.3c03345 · Cited by 22
Liu, J., Xiao, B., Yang, Y., Jiang, Y., Wang, R., Qi, W. D., Pan, Y., Chen, Y., Wang, H., Fan, J., et al. (2024) · ACS Nano · doi:10.1021/acsnano.4c06160 · Cited by 20
Nonviral targeted mRNA delivery: principles, progresses, and challenges
He, X., Li, G., Huang, L., Shi, H., Zhong, S., Zhao, S., Jiao, X., Xin, J., Yin, X., Liu, S., et al. (2025) · MedComm · doi:10.1002/mco2.70035 · Cited by 22
“112,113 It was reported that lipids containing alkenyl 114 or alkynyl groups 100 could facilitate the H II phase formation of LNPs. Siegwart et al. 115 reported a series of multi-tailed ionizable phospholipids (iPhos) capable of delivering mRNA or mRNA/single-guide RNA for gene editing in vivo.”
Self-citationMa, T., Chen, X., & Wang, M. (2023) · ChemBioChem · doi:10.1002/cbic.202200801 · Cited by 21
In Situ Programming of CAR-T Cells: A Pressing Need in Modern Immunotherapy
Śledź, M., Wojciechowska, A., Zagożdżon, R., & Kaleta, B. (2023) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-023-00683-y · Cited by 21
“An example of such an approach is adding the PD-1/CD28 chimeric switch-receptor, which increases the efficacy of therapy (Liu et al. 2021a).”
BackgroundLi, J., Hu, J., Jin, D., Huo, H., Chen, N., Lin, J., & Lu, X. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02919-1 · Cited by 24
“This high-throughput approach has led to the development of many ILs with high delivery efficiency and tissue-or cell-targeting capabilities [35–37].”
BackgroundEmerging lipid–polymer hybrid nanoparticles for genome editing
Gameiro, M. D., Mano, J. F., & Gaspar, V. M. (2024) · Polymer Chemistry · doi:10.1039/d4py00298a · Cited by 22
Iterative Screening of Vitamin E-Based Functional Lipid Nanoparticles for mRNA Delivery
Cui, K., Zhang, F., Shi, T., Zhao, S., Zhou, Y., Liu, X., Hu, Y. Y., Hu, Z., Kong, L., & Zhang, Z. (2025) · ACS Nano · doi:10.1021/acsnano.5c01378 · Cited by 20
Zhao, Y., Li, R., Liu, P., Wang, J., Cui, Y., Ma, Y., Cao, Z., Cui, M., Luozhong, S., Wagner, E. K., et al. (2025) · Nature Biomedical Engineering · doi:10.1038/s41551-025-01577-4 · Cited by 23
Metadata
- Authors
- Liu, S., Cheng, Q., Wei, T., Yu, X., Johnson, L. T., Farbiak, L., & Siegwart, D. J.
- Affiliations
- Harold C. Simmons Comprehensive Cancer Center (US)
- Corresponding author
- Siegwart, Daniel J.
- Venue
- Nature Materials
- Published
- 2021-02-04
- Volume
- 20
- Issue
- 5
- Pages
- 701-710
- ISSN
- 1476-1122 (ISSN-L)
- 1476-4660
- PMC
- PMC8188687
- OpenAlex
- W3127944141
- Cited by
- 653
- References
- 54
- Citations by year
- 2026: 107 · 2025: 154 · 2024: 139 · 2023: 122 · 2022: 90 · 2021: 40
- FWCI
- 30.66
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nature Materials (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Cancer Prevention and Research Institute of Texas (RP160157)
- U.S. Department of Health & Human Services | National Institutes of Health (R01 EB025192-01A1)
- American Cancer Society (RSG-17-012-01)
- Welch Foundation (I-1855)
- Cystic Fibrosis Foundation (SIEGWA18XX0)
- U.S. Department of Health & Human Services | NIH | National Cancer Institute (5P30CA142543)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Physical Sciences › Materials Science › Polymers and Plastics › Dendrimers and Hyperbranched Polymers
- Keywords
- endosomal escape, mRNA delivery, CRISPR/Cas9 genome editing, lipid nanoparticles, zwitterionic lipids, membrane perturbation, structure-activity relationship, helper lipids, nucleic acid therapeutics
- MeSH terms
- Gene Editing, Animals, Cell Line, Cell Membrane, Female, Organ Specificity, Phospholipids, RNA, Messenger, Drug Delivery Systems, Mice, Administration, Intravenous, CRISPR-Cas Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
